To the best of our knowledge, no study has yet explored whether the daily timing of anti-PD-1/PD-L1 immune checkpoint inhibitor drugs could moderate therapeutic efficacy in NSCLC patients. The gene discussed is CD274; the disease is non-small cell lung carcinoma.